Literature DB >> 9525641

Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines.

R J Wool-Lewis1, P Bates.   

Abstract

Studies analyzing Ebola virus replication have been severely hampered by the extreme pathogenicity of this virus. To permit analysis of the host range and function of the Ebola virus glycoprotein (Ebo-GP), we have developed a system for pseudotyping these glycoproteins into murine leukemia virus (MLV). This pseudotyped virus, MLV(Ebola), can be readily concentrated to titers which exceed 5 x 10(6) infectious units/ml and is effectively neutralized by antibodies specific for Ebo-GP. Analysis of MLV(Ebola) infection revealed that the host range conferred by Ebo-GP is very broad, extending to cells of a variety of species. Notably, all lymphoid cell lines tested were completely resistant to infection; we speculate that this is due to the absence of a cellular receptor for Ebo-GP on B and T cells. The generation of high-titer MLV(Ebola) pseudotypes will be useful for the analysis of immune responses to Ebola virus infection, development of neutralizing antibodies, analysis of glycoprotein function, and isolation of the cellular receptor(s) for the Ebola virus.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9525641      PMCID: PMC109772     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  31 in total

1.  Glycosylation and oligomerization of the spike protein of Marburg virus.

Authors:  H Feldmann; C Will; M Schikore; W Slenczka; H D Klenk
Journal:  Virology       Date:  1991-05       Impact factor: 3.616

2.  Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents.

Authors:  S Ohkuma; B Poole
Journal:  Proc Natl Acad Sci U S A       Date:  1978-07       Impact factor: 11.205

3.  Viral hepatitis, type B (MS-2 strain) prevention with specific hepatitis B immune serum globulin.

Authors:  S Krugman; J P Giles; J Hammond
Journal:  JAMA       Date:  1971-12-13       Impact factor: 56.272

4.  Ebola haemorrhagic fever in Zaire, 1976.

Authors: 
Journal:  Bull World Health Organ       Date:  1978       Impact factor: 9.408

5.  Filoviridae: a taxonomic home for Marburg and Ebola viruses?

Authors:  M P Kiley; E T Bowen; G A Eddy; M Isaäcson; K M Johnson; J B McCormick; F A Murphy; S R Pattyn; D Peters; O W Prozesky; R L Regnery; D I Simpson; W Slenczka; P Sureau; G van der Groen; P A Webb; H Wulff
Journal:  Intervirology       Date:  1982       Impact factor: 1.763

6.  Descriptive analysis of Ebola virus proteins.

Authors:  L H Elliott; M P Kiley; J B McCormick
Journal:  Virology       Date:  1985-11       Impact factor: 3.616

7.  Ebola haemorrhagic fever: experimental infection of monkeys.

Authors:  E T Bowen; G S Platt; D I Simpson; L B McArdell; R T Raymond
Journal:  Trans R Soc Trop Med Hyg       Date:  1978       Impact factor: 2.184

Review 8.  Virus entry into animal cells.

Authors:  M Marsh; A Helenius
Journal:  Adv Virus Res       Date:  1989       Impact factor: 9.937

9.  Cell fusion by Semliki Forest, influenza, and vesicular stomatitis viruses.

Authors:  J White; K Matlin; A Helenius
Journal:  J Cell Biol       Date:  1981-06       Impact factor: 10.539

10.  Inhibition of vesicular stomatitis virus infection by spike glycoprotein. Evidence for an intracellular, G protein-requiring step.

Authors:  D K Miller; J Lenard
Journal:  J Cell Biol       Date:  1980-02       Impact factor: 10.539

View more
  188 in total

1.  Retroviral vectors preloaded with a viral receptor-ligand bridge protein are targeted to specific cell types.

Authors:  A L Boerger; S Snitkovsky; J A Young
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-17       Impact factor: 11.205

2.  Human immunodeficiency virus type 1 particles pseudotyped with envelope proteins that fuse at low pH no longer require Nef for optimal infectivity.

Authors:  N Chazal; G Singer; C Aiken; M L Hammarskjöld; D Rekosh
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

3.  Soluble receptor-induced retroviral infection of receptor-deficient cells.

Authors:  R Damico; P Bates
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

4.  Membrane association induces a conformational change in the Ebola virus matrix protein.

Authors:  S Scianimanico; G Schoehn; J Timmins; R H Ruigrok; H D Klenk; W Weissenhorn
Journal:  EMBO J       Date:  2000-12-15       Impact factor: 11.598

5.  Functional importance of the coiled-coil of the Ebola virus glycoprotein.

Authors:  S Watanabe; A Takada; T Watanabe; H Ito; H Kida; Y Kawaoka
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

6.  Crystal structure of the matrix protein VP40 from Ebola virus.

Authors:  A Dessen; V Volchkov; O Dolnik; H D Klenk; W Weissenhorn
Journal:  EMBO J       Date:  2000-08-15       Impact factor: 11.598

7.  Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence.

Authors:  Graham Simmons; Rouven J Wool-Lewis; Frédéric Baribaud; Robert C Netter; Paul Bates
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

8.  Ebola virus VP40-induced particle formation and association with the lipid bilayer.

Authors:  L D Jasenosky; G Neumann; I Lukashevich; Y Kawaoka
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

9.  Inhibition of Marburg virus budding by nonneutralizing antibodies to the envelope glycoprotein.

Authors:  Masahiro Kajihara; Andrea Marzi; Eri Nakayama; Takeshi Noda; Makoto Kuroda; Rashid Manzoor; Keita Matsuno; Heinz Feldmann; Reiko Yoshida; Yoshihiro Kawaoka; Ayato Takada
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

10.  Severe fever with thrombocytopenia virus glycoproteins are targeted by neutralizing antibodies and can use DC-SIGN as a receptor for pH-dependent entry into human and animal cell lines.

Authors:  Heike Hofmann; Xingxing Li; Xiaoai Zhang; Wei Liu; Annika Kühl; Franziska Kaup; Samantha S Soldan; Francisco González-Scarano; Friedemann Weber; Yuxian He; Stefan Pöhlmann
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.